Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. Its polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to replace defective heart valves and blood vessels. ETR enables the patient’s natural healing system to develop tissue that spreads into the heart valve of Xeltis, building a new and natural valve inside with full functionality. The implants of Xeltis get absorbed by the body in the course of time. The company also operates research and development centers, manufacturing facility in Eindhoven, the Netherlands. Xeltis is headquartered in Zurich, Switzerland.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Xeltis AG
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Xeltis AG Company Overview
- Xeltis AG Company Snapshot
- Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
- Xeltis AG - Pipeline Analysis Overview
- Xeltis AG - Key Facts
- Xeltis AG - Major Products and Services
- Xeltis AG Pipeline Products by Development Stage
- Xeltis AG Ongoing Clinical Trials by Trial Status
- Xeltis AG Pipeline Products Overview
- Endogenous Tissue Restoration (ETR) Cardiovascular Graft
- Endogenous Tissue Restoration (ETR) Cardiovascular Graft Product Overview
- Pulmonary Pediatric Conduit
- Pulmonary Pediatric Conduit Product Overview
- Transcatheter Aortic Heart Valve
- Transcatheter Aortic Heart Valve Product Overview
- Xeltis Coronary Artery Bypass Graft
- Xeltis Coronary Artery Bypass Graft Product Overview
- Xeltis Coronary Artery Bypass Graft Clinical Trial
- Xeltis Hemodialysis Vascular Access Graft
- Xeltis Hemodialysis Vascular Access Graft Product Overview
- Xeltis Hemodialysis Vascular Access Graft Clinical Trial
- Xeltis Pulmonary Valve
- Xeltis Pulmonary Valve Product Overview
- Xeltis Pulmonary Valve Clinical Trial
- Xeltis AG - Key Competitors
- Xeltis AG - Key Employees
- Xeltis AG - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Xeltis AG, Recent Developments
- Feb 21, 2023: Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices
- Jun 25, 2018: The Children’s Hospital of Pittsburgh of UPMC joins the Xplore-2 trial
- Jun 22, 2018: Children’s Hospital Los Angeles joins the Xplore-2 Study
- Jun 13, 2018: Xeltis restorative technology for aortic valves at ISMICS
- Jun 01, 2018: Preliminary Xplore-1 data show promise at ECHSA
- May 30, 2018: Preliminary Xplore-1 data at ECHSA
- May 22, 2018: Xeltis aortic valve program in focus at EuroPCR
- May 14, 2018: Xeltis’ restorative technology at ICTEHV
- Apr 13, 2018: Xeltis’ restorative aortic valves show promise at HVS
- Apr 06, 2018: Xeltis’ restorative aortic valves at HVS
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview
- Xeltis AG Pipeline Products by Equipment Type
- Xeltis AG Pipeline Products by Indication
- Xeltis AG Ongoing Clinical Trials by Trial Status
- Xeltis AG, Key Facts
- Xeltis AG, Major Products and Services
- Xeltis AG Number of Pipeline Products by Development Stage
- Xeltis AG Pipeline Products Summary by Development Stage
- Xeltis AG Ongoing Clinical Trials by Trial Status
- Xeltis AG Ongoing Clinical Trials Summary
- Endogenous Tissue Restoration (ETR) Cardiovascular Graft - Product Status
- Endogenous Tissue Restoration (ETR) Cardiovascular Graft - Product Description
- Pulmonary Pediatric Conduit - Product Status
- Pulmonary Pediatric Conduit - Product Description
- Transcatheter Aortic Heart Valve - Product Status
- Transcatheter Aortic Heart Valve - Product Description
- Xeltis Coronary Artery Bypass Graft - Product Status
- Xeltis Coronary Artery Bypass Graft - Product Description
- Xeltis Coronary Artery Bypass Graft - Prospective, Non-randomized, First in Human (FIH) Clinical Study to Assess the Feasibility of the Novel Xeltis Coronary Artery Bypass Graft (XABG)
- Xeltis Hemodialysis Vascular Access Graft - Product Status
- Xeltis Hemodialysis Vascular Access Graft - Product Description
- Xeltis Hemodialysis Vascular Access Graft - First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft (aXess)
- Xeltis Hemodialysis Vascular Access Graft - Prospective, Non-randomized Pivotal Clinical Study to Assess the Safety and Performance of the Xeltis Hemodialysis Access Graft: aXess Pivotal Study
- Xeltis Pulmonary Valve - Product Status
- Xeltis Pulmonary Valve - Product Description
- Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
- Xeltis Pulmonary Valve - Prospective, Non-randomized, Pivotal Study to Assess the Safety and Efficacy of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
- Xeltis AG, Key Employees
- Xeltis AG, Subsidiaries
- Glossary
- Xeltis AG Pipeline Products by Equipment Type
- Xeltis AG Pipeline Products by Development Stage
- Xeltis AG Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Symetis SA
- Sequana Medical NV
- Abionic SA
- Symetis SA
- Sequana Medical NV
- Abionic SA
